Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Live Nation Entertainment, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Live Nation Entertainment, Inc. trades at $180.84 (market cap $42.25B). The key difference: Live Nation Entertainment, Inc. is far larger — about 5.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | LYV | |
|---|---|---|
Market Cap | $8.04B | $42.25B |
Sector | Health | Industrials |
52-Week High | $339.75 | $186.59 |
52-Week Low | $241.71 | $125.61 |
Enterprise Value | $7.85B | $43.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Live Nation (LYV) trades at $183.25, up 1.92% with strong analyst support (88.6% buy ratings) and a $200.20 consensus target. The stock shows bullish technical signals with support at $178 and resistance at $185. Despite recent earnings misses, revenue grew to $25.2B in 2025, though net margins remain thin at 0.33% with negative ROE of -24.68%.
The outlook remains positive given strong concert demand and ticketing dominance, but elevated valuation (P/E 117.5) and regulatory scrutiny pose risks. Cash flow improved to $1.0B net in 2025, supporting growth investments. Institutional sentiment favors upside to price targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
